Establishment Labs Holdings Inc - ESTA STOCK NEWS

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its participation in The Aesthetic Meeting 2024, where Dr. Caroline Glicksman will present an update on the Motiva US Core Clinical Study. The company's silicone gel-filled implants are undergoing PMA clinical investigation in the US.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced its financial results for Q4 and full year 2023, with a revenue guidance of $174-184 million for 2024. The company reported Q4 revenue of $31.6 million, a net loss of $22.1 million, and a proforma cash balance of $90 million. The CEO highlighted market stabilization, expense reduction, and positive growth outlook for 2024.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announces participation in two upcoming investment conferences. CEO and CFO to speak at Citi's 2024 Unplugged Medtech and Life Sciences Access Day and TD Cowen 44th Annual Health Care Conference.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) amends its term loan facility with Oaktree Capital Management, L.P. to secure $50 million additional capital for the launch of Motiva Implants® in the U.S. The terms for the $175 million already drawn remain unchanged, while the remaining $50 million will be available upon FDA approval and sales milestones. Interest on the new tranches will accrue at a fixed rate of 10.0% per annum.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) will announce its financial results for the quarter ended December 31, 2023, on February 28, 2024. The company focuses on women's health and wellness, particularly in breast aesthetics and reconstruction.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) has announced the launch of Motiva® Implants in China, the second largest market globally. The company expects rapid growth in China due to consumer appreciation for innovative technologies and a large segment willing to pay a premium for such products. The commercial launch coincided with the Motiva China International Academic Conference, and events also took place in Shanghai, Guangzhou, and Shenzhen. Establishment Labs received National Medical Products Administration (NMPA) approval in China for Motiva® Implants in November 2023.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced a securities purchase agreement with institutional accredited investors to purchase common shares or pre-funded warrants. Preliminary unaudited financial results for Q4 2023 show expected revenue in the range of $31.4 million to $31.8 million, in line with previous guidance. Full-year 2023 revenue is expected to be $165.0 million to $165.4 million, with a year-end cash position of approximately $39.1 million. The company will sell two million common shares or pre-funded warrants at $25.00 per share, expecting aggregate gross proceeds of approximately $50 million.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announced that the Motiva Flora® SmoothSilk® Tissue Expander was used for the first time in the United States at the University of Texas MD Anderson Cancer Center in Houston by Mark Clemens, MD MBA FACS, Professor of Plastic Surgery. The recent FDA clearance and first procedure mark significant developments in the field of plastic and reconstructive surgery. The Flora® Tissue Expander includes several proprietary innovations, including Establishment Labs’ patented SmoothSilk® surface technology and an RFID-enabled, non-magnetic port, labeled as MR Conditional by the FDA. SmoothSilk® has been shown to produce the least amount of inflammation and foreign body response compared to other device surfaces. By being magnet-free, Flora avoids the interference that magnets cause during MRI and may improve the precision of radiation oncology treatment. Juan José Chacón-Quirós, Founder and CEO of Establishment Labs, emphasized the company's commitment to improving women’s health and wellness, stating that real innovation leads to better patient outcomes, and Flora is setting a new standard in breast reconstruction.

Establishment Labs Holdings Inc. (NASDAQ: ESTA) announces participation in the 42nd Annual J.P. Morgan Healthcare Conference